3PBIOVIAN service offering includes microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production, with the provision for fill and finish services for recombinant proteins and viral vectors. Leveraging a combined track record of 40 years in process development and analytical methods development, complemented by the experience in process scale-up, GMP manufacturing, and commercial supply, 3PBIOVIAN is equipped to offer comprehensive manufacturing services at all stages, encompassing Drug Substance and Drug Product. Manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland seamlessly support the diverse needs of clients, covering pre-clinical and clinical supply to full-scale commercial manufacturing.
| Website | https://3pbiovian.com |
| Revenue | $81 million |
| Employees | 388 (298 on RocketReach) |
| Founded | 2024 |
| Industry | Pharmaceutical Manufacturing |
| Keywords | Protein Expression, Viral Vector Production, Cell Therapy, Biologics Manufacturing, Microbial Protein, Fill Finish Services, Gene Therapy, Adeno Associated Virus, Contract Manufacturing Organization, Cmo Services, Pharmaceutical Manufacturing, Biopharmaceutical Manufacturing, Process Development, Drug Substance |
| Competitors | Abzena, Celerion, Takeda, Lonza, WuXi AppTec, Sartorius, Catalent Pharma Solutions, MedImmune, Parexel, Charles River Laboratories +44 more (view full list) |
Looking for a particular 3PBIOVIAN employee's phone or email?
The 3PBIOVIAN annual revenue was $81 million in 2026.
Tim Cinq-Mars is the Associate Director of Business Development of 3PBIOVIAN.
298 people are employed at 3PBIOVIAN.